NCT00143416已完成3 期
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 16
- 试验地点
- 8
- 主要终点
- To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly
研究概览
简要总结
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).
排除标准
- •Switching to other therapeutic methods for acromegaly
结局指标
主要结局
To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly
次要结局
- PK/PD evaluation
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic PatientsAcromegalyImpaired Glucose ToleranceInsulin ResistanceNCT00652379University of Aarhus18
已完成
不适用
Tissue Biomarker for Pegvisomant ActionAcromegalyNCT01261000Cedars-Sinai Medical Center8
已完成
3 期
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPImmune ThrombocytopeniaNCT05369208Sobi, Inc.19
已完成
不适用
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryAcromegalyNCT00500227Ipsen55
Unknown
不适用
A Pilot Study of Empagliflozin in the Treatment of Acromegalic CardiomyopathyCardiomyopathiesAcromegalyNCT04520646Huashan Hospital10